Wang Likui1, Wang Hong, Zhang Shuwen, You Yuangang, Wen Yan. 1. Department of Infection, Beijing Friendship Hospital, Capital Medical University, 95 Yong-An Road, Beijing 100050, People's Republic of China. kui_li2008@yahoo.com.cn
Abstract
OBJECTIVE: Osteopontin (OPN), a phosphorylated glycoprotein, is involved in tumor progression and metastasis. Previously, we have reported that high OPN mRNA expression level possessed clinicopathological or prognostic significance in human colorectal cancer (CRC). The aim of this study is to investigate whether OPN can serve as a novel molecular target for CRC therapy. MATERIAL AND METHODS: Western Blot assay was performed to detect the expression of OPN protein in 18 CRC and corresponding nontumor colon tissue samples. RNA interference (RNAi) was employed to knockdown endogenous OPN expression in CRC cell line (LoVo). MTT, colony formation, and tumorigenicity assays were performed to analyze the effect of OPN downregulation on the in vitro and in vivo proliferation of CRC cells. Wound healing and Matrigel invasion assays were performed to analyze the effect of OPN downregulation on migration and invasion of CRC cells. A clonogenic cell survival assay after radiation was performed to analyze the effect of OPN downregulation on the radiosensitivity of CRC cells. RESULTS: The relative level of OPN protein expression in CRC tissues was significantly higher than that in corresponding nontumor colon tissues (P < 0.05). We found that RNAi-mediated OPN downregulation could inhibit not only in vitro proliferation but also in vivo tumorigenicity of CRC cells. In addition, OPN downregulation could suppress in vitro invasion capacity and enhance in vitro radiosensitivity of CRC cells, which might be associated with decreased levels of MMP-2 and -9 expression. CONCLUSION: RNAi-targeting OPN could inhibit proliferation, invasion and enhance radiosensitivity of human CRC cells. Therefore, OPN could serve as a novel molecular target for gene therapy of CRC.
OBJECTIVE:Osteopontin (OPN), a phosphorylated glycoprotein, is involved in tumor progression and metastasis. Previously, we have reported that high OPN mRNA expression level possessed clinicopathological or prognostic significance in humancolorectal cancer (CRC). The aim of this study is to investigate whether OPN can serve as a novel molecular target for CRC therapy. MATERIAL AND METHODS: Western Blot assay was performed to detect the expression of OPN protein in 18 CRC and corresponding nontumor colon tissue samples. RNA interference (RNAi) was employed to knockdown endogenous OPN expression in CRC cell line (LoVo). MTT, colony formation, and tumorigenicity assays were performed to analyze the effect of OPN downregulation on the in vitro and in vivo proliferation of CRC cells. Wound healing and Matrigel invasion assays were performed to analyze the effect of OPN downregulation on migration and invasion of CRC cells. A clonogenic cell survival assay after radiation was performed to analyze the effect of OPN downregulation on the radiosensitivity of CRC cells. RESULTS: The relative level of OPN protein expression in CRC tissues was significantly higher than that in corresponding nontumor colon tissues (P < 0.05). We found that RNAi-mediated OPN downregulation could inhibit not only in vitro proliferation but also in vivo tumorigenicity of CRC cells. In addition, OPN downregulation could suppress in vitro invasion capacity and enhance in vitro radiosensitivity of CRC cells, which might be associated with decreased levels of MMP-2 and -9 expression. CONCLUSION: RNAi-targeting OPN could inhibit proliferation, invasion and enhance radiosensitivity of human CRC cells. Therefore, OPN could serve as a novel molecular target for gene therapy of CRC.
Authors: Philip Y Wai; Zhiyong Mi; Hongtao Guo; Shiva Sarraf-Yazdi; Chengjiang Gao; Junping Wei; Carlos E Marroquin; Bryan Clary; Paul C Kuo Journal: Carcinogenesis Date: 2005-01-20 Impact factor: 4.944
Authors: Virginie Lamour; Marie Le Mercier; Florence Lefranc; Martin Hagedorn; Sophie Javerzat; Andreas Bikfalvi; Robert Kiss; Vincent Castronovo; Akeila Bellahcène Journal: Int J Cancer Date: 2010-04-15 Impact factor: 7.396
Authors: Zhiyong Mi; Hongtao Guo; M Benjamin Russell; Yingmiao Liu; Bruce A Sullenger; Paul C Kuo Journal: Mol Ther Date: 2008-11-04 Impact factor: 11.454
Authors: Victoria Catalán; Javier Gómez-Ambrosi; Amaia Rodríguez; Beatriz Ramírez; Maitane Izaguirre; José Luis Hernández-Lizoain; Jorge Baixauli; Pablo Martí; Víctor Valentí; Rafael Moncada; Camilo Silva; Javier Salvador; Gema Frühbeck Journal: PLoS One Date: 2016-09-09 Impact factor: 3.240
Authors: Akram Mirzaei; Saeed Mohammadi; Seyed H Ghaffari; Marjan Yaghmaie; Mohammad Vaezi; Kamran Alimoghaddam; Ardeshir Ghavamzadeh Journal: Asian Pac J Cancer Prev Date: 2018-03-27